PALO ALTO, Calif., May 11, 2011 /PRNewswire/ — Varian Medical
Systems (NYSE:
VAR) will showcase the company’s full spectrum of prostate
cancer treatment technologies at the upcoming American Urological
Association (AUA) Meeting in Washington, D.C. During the
meeting, Varian will sponsor a series of presentations covering
emerging treatments and multi-disciplinary approaches to prostate
cancer care.
Within the company’s exhibit, Varian will showcase its latest
solutions for high- and low-dose-rate brachytherapy,
intensity-modulated radiotherapy (IMRT), and stereotactic body
radiotherapy (SBRT), an emerging and promising new approach that
involves delivering higher doses to the prostate over a shorter
time period than would be the case with conventional radiotherapy.
“Varian offers state-of-the-art technology for all of the
commonly-used radiotherapy approaches to treating prostate cancer,”
said Calvin Huntzinger, MS, senior director, Varian Surgical
Sciences.
Presentations Explore New Options in Prostate Cancer
Care
On Sunday, May 15, and again on Monday, May 16, a select group
of eminent surgeons, urologists, radiation oncologists, and
researchers will deliver 20-minute mini-lectures on major advances
in their fields of specialization, with a particular focus on how
multidisciplinary collaboration can benefit patients. The
lectures will take place in the Varian booth (#3043). The
presentations will include:
- Constantine A. Mantz, MD, chief medical officer at 21st Century
Oncology in Fort Myers, Florida, on stereotactic body radiotherapy
(SBRT) as an emerging treatment for prostate cancer. Dr.
Mantz has been conducting Phase II SBRT trials using Varian
technology to deliver five treatments over a two-week period, with
promising preliminary results that appear to support the use of
SBRT‘/>”/>
SOURCE